Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention

NCT01012193 is registered in ClinicalTrials.gov with Gyeongsang National University Hospital as lead sponsor.

NCT NCT01012193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01012193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention
Lead sponsor
Gyeongsang National University Hospital
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2008
Completion date
September 30, 2009
Enrollment
134 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, percutaneous coronary intervention